RxDoctor Payments DataLook up a doctor →

Robert Segal, MD

Infectious Disease · Hillsborough, NJNPI 1265408264

Payments from drug & device makers

$40,903in general payments, 2019–2025

Across 493 payments — averaging $82.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Merck$9K
  • Shionogi Inc$4K
  • Gilead$2K
  • Organogenesis Inc.$1K
  • Viiv Healthcare Company$980
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$6902%
  • Speaking & faculty fees$29,29272%
  • Travel & lodging$9792%
  • Food & beverage$9,88924%
  • Education$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,903 in reported general payments places this provider in the 90th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$241,665
Medicare patients
812
Services billed
6,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala86$335,224
DovatoDolutegravir Sodium/Lamivudine95$286,729
GenvoyaElviteg/Cob/Emtri/Tenof Alafen53$220,897
TriumeqAbacavir/Dolutegravir/Lamivudi29$105,419
TivicayDolutegravir Sodium27$89,853
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$55,705
DescovyEmtricitabine/Tenofov Alafenam13$29,859
IsentressRaltegravir Potassium22$24,574
Daptomycin19$6,100
Darunavir12$5,940
AbacavirAbacavir Sulfate12$4,236
Cefpodoxime Proxetil17$2,390
Testosterone11$2,076
Cefadroxil53$1,535
Vancomycin Hcl17$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,889$585,979152 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay$980$482,002151 claims
Janssen Products, LPSymtuza$29$55,70512 claims
MerckIsentress$8,515$24,57422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in Hillsborough

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →